Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

RCT found addition of isatuximab to carfilzomib–dexamethasone improved progression-free survival in 302 patients with pre-treated disease (median survival not reached vs 19 months with carfilzomib–dexamethasone alone; HR 0.53; 99% CI 0.32–0.89-).

Source:

The Lancet